華海清科(688120.SH):“華海清科集成電路高端裝備研發及產業化項目”建設週期預計為26個月
格隆匯12月7日丨華海清科(688120.SH)近期披露投資者關係活動記錄表顯示,公司全資子公司華海清科北京在北京經濟技術開發區實施“華海清科集成電路高端裝備研發及產業化項目”,用於公司開展化學機械拋光設備、減薄設備、濕法設備等高端半導體設備研發及產業化,建設週期預計為26個月。隨着我國集成電路發展成為國家重點戰略和全球貿易環境日趨複雜,對半導體專用設備的國產化需求愈發迫切且增長迅速,公司需要前瞻性地擴大生產能力來滿足快速增長的市場需求,本項目將進一步擴大公司生產經營規模和提高技術研發實力,從而提升公司核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.